Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase NA 1Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Prostatic Neoplasms 7Squamous Cell Carcinoma of Head and Neck 4Carcinoma, Non-Small-Cell Lung 4Esophageal Neoplasms 3Stomach Neoplasms 2Oropharyngeal Neoplasms 2Multiple Myeloma 2Mouth Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myeloid, Acute 2Endometrial Neoplasms 2Colorectal Neoplasms 2Breast Neoplasms 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Tongue Neoplasms 1Retinoblastoma 1Recurrence 1Rectal Neoplasms 1Precancerous Conditions 1Pancreatic Neoplasms 1Osteoporosis 1Obesity 1Neoplasms 1Neoplasm Metastasis 1Meningioma 1Melanoma 1Lymphoma, Mantle-Cell 1

Interventions

Cyclophosphamide 146Rituximab 138fludarabine phosphate 111Mycophenolic Acid 69Peripheral Blood Stem Cell Transplantation 63fludarabine 59Tacrolimus 58Whole-Body Irradiation 51venetoclax 46Busulfan 46ibrutinib 45Cyclosporine 42Lenalidomide 41Filgrastim 41Alemtuzumab 41Melphalan 40Radiotherapy 39obinutuzumab 37Antilymphocyte Serum 35Etoposide 33Methotrexate 32ofatumumab 29acalabrutinib 26Bendamustine Hydrochloride 24sargramostim 22Methylprednisolone 18Cytarabine 18zanubrutinib 17Pentostatin 17Granulocyte Colony-Stimulating Factor 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Leukemia, Lymphocytic, Chronic, B-Cell × Observation × Clear all
NCT03516617 2026-02-09

Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Mayo Clinic

Phase 2 Recruiting
120 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡